Royalty Pharma plc Increase (Decrease) in Other Current Assets
Royalty Pharma plc (RPRX) reported Increase (Decrease) in Other Current Assets of $3.60 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOtherCurrentAssets · last filed 2026-08-05
- Royalty Pharma plc increase (decrease) in other current assets for the quarter ending 2026-06-30 was -$1.62M, a 163.07% decline year-over-year.
- Royalty Pharma plc increase (decrease) in other current assets for the quarter ending 2026-03-31 was $5.23M.
- Royalty Pharma plc increase (decrease) in other current assets for the quarter ending 2025-12-31 was $3.20M.
- Royalty Pharma plc increase (decrease) in other current assets for the quarter ending 2025-09-30 was $3.06M, a 13.02% increase year-over-year.
- Royalty Pharma plc increase (decrease) in other current assets for fiscal 2025 was $7.72M.
- Royalty Pharma plc increase (decrease) in other current assets for fiscal 2024 was -$13.84M.
- Royalty Pharma plc increase (decrease) in other current assets for fiscal 2023 was -$3.15M.
- Royalty Pharma plc increase (decrease) in other current assets for fiscal 2022 was -$38.65M.
| Period end | Increase (Decrease) in Other Current Assets 3 month | Increase (Decrease) in Other Current Assets 3 month as first filed | Increase (Decrease) in Other Current Assets 6 month | Increase (Decrease) in Other Current Assets 6 month as first filed | Increase (Decrease) in Other Current Assets 9 month | Increase (Decrease) in Other Current Assets 9 month as first filed | Increase (Decrease) in Other Current Assets 12 month | Increase (Decrease) in Other Current Assets 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$1.62M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $3.60M 10-Q · filed 2026-08-05 | $6.80M derived: sum of 3 quarters · filed 2026-08-05 | $9.86M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2026-03-31 | $5.23M 10-Q · filed 2026-05-06 | $8.43M derived: sum of 2 quarters · filed 2026-05-06 | $11.48M derived: sum of 3 quarters · filed 2026-05-06 | $14.06M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2025-12-31 | $3.20M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | $6.26M derived: sum of 2 quarters · filed 2026-02-11 | $8.83M derived: sum of 3 quarters · filed 2026-08-05 | $7.72M 10-K · filed 2026-02-11 | ||||
| 2025-09-30 | $3.06M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $5.63M derived: sum of 2 quarters · filed 2026-08-05 | $4.52M 10-Q · filed 2025-11-05 | $3.75M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2025-06-30 | $2.58M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $1.47M 10-Q · filed 2026-08-05 | $691.00K derived: sum of 3 quarters · filed 2026-08-05 | $3.40M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2025-03-31 | -$1.11M 10-Q · filed 2026-05-06 | -$1.88M derived: sum of 2 quarters · filed 2026-05-06 | $820.00K derived: sum of 3 quarters · filed 2026-05-06 | -$1.92M derived: sum of 4 quarters · filed 2026-05-06 | ||||
| 2024-12-31 | -$776.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | $1.93M derived: sum of 2 quarters · filed 2026-02-11 | -$816.00K derived: sum of 3 quarters · filed 2026-02-11 | -$13.84M 10-K · filed 2026-02-11 | ||||
| 2024-09-30 | $2.70M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | -$40.00K derived: sum of 2 quarters · filed 2025-11-05 | -$13.07M 10-Q · filed 2025-11-05 | -$18.16M derived: sum of 4 quarters · filed 2026-02-11 | ||||
| 2024-06-30 | -$2.74M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | -$15.77M 10-Q · filed 2025-08-06 | -$20.86M derived: sum of 3 quarters · filed 2026-02-11 | -$24.30M derived: sum of 4 quarters · filed 2026-02-11 | ||||
| 2024-03-31 | -$13.03M 10-Q · filed 2025-05-08 | -$18.12M derived: sum of 2 quarters · filed 2026-02-11 | -$21.56M derived: sum of 3 quarters · filed 2026-02-11 | -$15.90M derived: sum of 4 quarters · filed 2026-02-11 | ||||
| 2023-12-31 | -$5.09M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | -$8.53M derived: sum of 2 quarters · filed 2026-02-11 | -$2.87M derived: sum of 3 quarters · filed 2026-02-11 | -$3.15M 10-K · filed 2026-02-11 | -$559.00K 10-K · filed 2024-02-15 | |||
| 2023-09-30 | -$3.44M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $2.22M derived: sum of 2 quarters · filed 2024-11-06 | $1.94M 10-Q · filed 2024-11-06 | $2.41M 10-Q · filed 2023-11-08 | -$28.46M derived: sum of 4 quarters · filed 2025-02-12 | |||
| 2023-06-30 | $5.66M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $5.38M 10-Q · filed 2024-08-08 | $5.85M 10-Q · filed 2023-08-08 | -$25.02M derived: sum of 3 quarters · filed 2025-02-12 | -$30.56M derived: sum of 4 quarters · filed 2025-02-12 | |||
| 2023-03-31 | -$275.00K 10-Q · filed 2024-05-09 | $199.00K 10-Q · filed 2023-05-09 | -$30.68M derived: sum of 2 quarters · filed 2025-02-12 | -$36.22M derived: sum of 3 quarters · filed 2025-02-12 | -$37.69M derived: sum of 4 quarters · filed 2025-02-12 | |||
| 2022-12-31 | -$30.40M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-12 | -$35.94M derived: sum of 2 quarters · filed 2025-02-12 | -$37.41M derived: sum of 3 quarters · filed 2025-02-12 | -$38.65M 10-K · filed 2025-02-12 | -$2.20M 10-K · filed 2023-02-15 | |||
| 2022-09-30 | -$5.54M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | -$7.01M derived: sum of 2 quarters · filed 2023-11-08 | -$8.25M 10-Q · filed 2023-11-08 | -$10.58M derived: sum of 4 quarters · filed 2024-02-15 | ||||
| 2022-06-30 | -$1.47M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | -$2.71M 10-Q · filed 2023-08-08 | -$5.04M derived: sum of 3 quarters · filed 2024-02-15 | -$865.00K derived: sum of 4 quarters · filed 2024-02-15 | ||||
| 2022-03-31 | -$1.24M 10-Q · filed 2023-05-09 | -$3.57M derived: sum of 2 quarters · filed 2024-02-15 | $604.00K derived: sum of 3 quarters · filed 2024-02-15 | -$1.16M derived: sum of 4 quarters · filed 2024-02-15 | ||||
| 2021-12-31 | -$2.33M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-15 | $1.85M derived: sum of 2 quarters · filed 2024-02-15 | $82.00K derived: sum of 3 quarters · filed 2024-02-15 | -$1.86M 10-K · filed 2024-02-15 | ||||
| 2021-09-30 | $4.18M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $2.41M derived: sum of 2 quarters · filed 2022-11-08 | $473.00K 10-Q · filed 2022-11-08 | -$2.68M derived: sum of 4 quarters · filed 2023-02-15 | ||||
| 2021-06-30 | -$1.76M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | -$3.70M 10-Q · filed 2022-08-04 | -$6.85M derived: sum of 3 quarters · filed 2023-02-15 | -$51.32M derived: sum of 4 quarters · filed 2023-02-15 | ||||
| 2021-03-31 | -$1.94M 10-Q · filed 2022-05-05 | -$5.09M derived: sum of 2 quarters · filed 2023-02-15 | -$49.56M derived: sum of 3 quarters · filed 2023-02-15 | -$36.88M derived: sum of 4 quarters · filed 2023-02-15 | ||||
| 2020-12-31 | -$3.15M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-15 | -$47.62M derived: sum of 2 quarters · filed 2023-02-15 | -$34.95M derived: sum of 3 quarters · filed 2023-02-15 | -$34.99M 10-K · filed 2023-02-15 | $10.28M 10-K · filed 2021-02-24 | |||
| 2020-09-30 | -$44.47M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | -$31.80M derived: sum of 2 quarters · filed 2021-11-10 | -$31.84M 10-Q · filed 2021-11-10 | $12.94M 10-Q · filed 2020-11-12 | $13.70M derived: sum of 4 quarters · filed 2022-02-15 | |||
| 2020-06-30 | $12.67M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-11 | $12.63M 10-Q · filed 2021-08-11 | $58.16M derived: sum of 3 quarters · filed 2022-02-15 | $57.83M derived: sum of 4 quarters · filed 2022-02-15 | ||||
| 2020-03-31 | -$40.00K 10-Q · filed 2021-05-11 | $45.49M derived: sum of 2 quarters · filed 2022-02-15 | $45.16M derived: sum of 3 quarters · filed 2022-02-15 | |||||
| 2019-12-31 | $45.53M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-15 | $45.20M derived: sum of 2 quarters · filed 2022-02-15 | $41.03M 10-K · filed 2022-02-15 | -$4.61M 10-K · filed 2021-02-24 | ||||
| 2019-09-30 | -$331.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-12 | -$4.50M 10-Q · filed 2020-11-12 | ||||||
| 2019-06-30 | -$4.17M 10-Q · filed 2020-08-12 | |||||||
| 2018-12-31 | $442.00K 10-K · filed 2021-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |